Login / Signup

Phase I study of Androgen deprivation therapy in combination with anti-PD-1 in patients pre- treated with anti-PD-1.

Caroline RobertCeleste LebbèThierry LesimpleEija LundströmValérie NicolasBruno GavilletPhilippa CromptonBaryour BaroudijianÉmilie RoutierFerdy J Lejeune
Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
This combination was well tolerated. Disease control in 42.8% (RECIST) and 50% (iRECIST).Thymus rejuvenation was limited.
Keyphrases
  • newly diagnosed
  • end stage renal disease
  • ejection fraction
  • prognostic factors
  • stem cells
  • mesenchymal stem cells
  • bone marrow
  • platelet rich plasma
  • smoking cessation